| NHS England | NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin | | 2026-01-30 |
| Regional Business Services Organisation, Procurement and Logistics Service | Generic, Branded Generic & Proprietary Medicinal Products - Group 17 | | 2026-01-12 |
| Regional Business Services Organisation, Procurement and Logistics Service | Generic, Branded Generic & Proprietary Medicinal Products - Group 16 | | 2025-08-21 |
| Procurement & Logistics Service | Generic, Branded Generic & Proprietary Medicinal Products - Group 15 | | 2025-01-24 |
| Procurement & Logistics Service | Generic, Branded Generic & Proprietary Medicinal Products - Group 14 | | 2024-08-15 |
| Regional Business Services Organisation, Procurement and Logistics Service | Generic, Branded Generic & Proprietary Medicinal Products - Group 18 | | 2026-07-03 |